Yuki Nakanishi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yuki Nakanishi has a total of 273 co-authors. Here are the top co-authors by number of shared publications:
Hiroshi Seno
Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
10 shared publications- Hiroshi Seno
Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
9 shared publications - Akihisa Fukuda
Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
7 shared publications - Takaaki Yoshikawa
Department of Gastroenterology and Hepatology, Medical Research Institute Kitano Hospital, Osaka, Japan
7 shared publications - Hiroaki Kasashima
Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan
6 shared publications - Yu Muta
Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
6 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
Tumor-Promoting Inflammation in Serrated Colorectal Neoplasia: Immune Ecosystems and Clinical Implications
Jiayu Chen, Yuki Nakanishi, Xiaomeng Yin, Mami Bamba, Yu Muta, Takahiro Utsumi, Hiroaki Kasashima, Akihisa Fukuda, Hiroshi Seno. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl260271
- 29 September 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
Open AccessTumor-Promoting Inflammation in Serrated Colorectal Neoplasia: Immune Ecosystems and Clinical Implications
Jiayu Chen, Yuki Nakanishi, Xiaomeng Yin, Mami Bamba, Yu Muta, Takahiro Utsumi, Hiroaki Kasashima, Akihisa Fukuda, Hiroshi Seno. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl260271
- Open Access
- 1 June 2026
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 17 (3) , 187
Natural product-based nanoengineering in gastrointestinal stromal tumors: early promise and translational challenges
Natural product-based nanoengineering in gastrointestinal stromal tumors: early promise and translational challenges
- 1 June 2026
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 17 (3) , 187
Open AccessNatural product-based nanoengineering in gastrointestinal stromal tumors: early promise and translational challenges
Natural product-based nanoengineering in gastrointestinal stromal tumors: early promise and translational challenges
- Open Access
From inflammation to malignancy: the dynamic evolution of cancer-associated fibroblasts in IBD-CRC
- Open Access
- 17 February 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (7)
Corrigendum to Polybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer
- 17 February 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (7)
Open AccessCorrigendum to Polybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer
- Open Access
- 23 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Targeting fibroblast derived thrombospondin 2 disrupts an immune-exclusionary environment at the tumor front in colorectal cancer
Fibrotic colorectal cancers (CRC) are largely microsatellite-stable and display desmoplastic stroma with poor immune infiltration. Here we identify thrombospondin-2 (THBS2) as a key regulator of the immune-exclusionary phenotype in fibrotic CRC. THBS2 is highly expressed by matrix cancer-associated fibroblasts at the tumor front. In an orthotopic model using desmoplastic tumor organoids, global or fibroblast-specific Thbs2 deletion disrupts the exclusionary barrier and increases intratumoral CD8 T cells. Mechanistically, THBS2 limits recruitment of CXCR3+ CD8 T cells by restraining dendritic- and macrophage-derived CXCL9/10. Depletion of these myeloid cells or blockade of CXCL9/10-CXCR3 signaling abolishes the enhanced CD8 T-cell influx and antitumor efficacy. Spatial profiling demonstrates that THBS2 loss induces proximity between CD8 T cells and myeloid cells and upregulates chemokines. Despite increased infiltration, CD8 T cells manifest exhaustion, rendering tumors highly susceptible to immune checkpoint blockade. THBS2 thus represents a tractable CAF-restricted target to overcome immune exclusion in fibrotic CRCs.
- 23 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Open AccessTargeting fibroblast derived thrombospondin 2 disrupts an immune-exclusionary environment at the tumor front in colorectal cancer
Fibrotic colorectal cancers (CRC) are largely microsatellite-stable and display desmoplastic stroma with poor immune infiltration. Here we identify thrombospondin-2 (THBS2) as a key regulator of the immune-exclusionary phenotype in fibrotic CRC. THBS2 is highly expressed by matrix cancer-associated fibroblasts at the tumor front. In an orthotopic model using desmoplastic tumor organoids, global or fibroblast-specific Thbs2 deletion disrupts the exclusionary barrier and increases intratumoral CD8 T cells. Mechanistically, THBS2 limits recruitment of CXCR3+ CD8 T cells by restraining dendritic- and macrophage-derived CXCL9/10. Depletion of these myeloid cells or blockade of CXCL9/10-CXCR3 signaling abolishes the enhanced CD8 T-cell influx and antitumor efficacy. Spatial profiling demonstrates that THBS2 loss induces proximity between CD8 T cells and myeloid cells and upregulates chemokines. Despite increased infiltration, CD8 T cells manifest exhaustion, rendering tumors highly susceptible to immune checkpoint blockade. THBS2 thus represents a tractable CAF-restricted target to overcome immune exclusion in fibrotic CRCs.
- 7 November 2025
- Published by Springer Nature in Surgical Endoscopy
- p. 1-12
Factors associated with adverse events and three-year survival following endoscopic submucosal dissection for early gastric cancer in patients aged 85 years or older
Background Endoscopic submucosal dissection (ESD) is a safe and minimally invasive procedure for early gastric cancer (EGC). However, little is known about the adverse events and prognosis of gastric ESD in much older adult patients with age-related comorbidities. Therefore, we aimed to elucidate factors associated with the adverse events and prognosis of ESD for EGC in patients ≥ 85 years. Methods We enrolled 853 patients with 920 lesions ≥ 85 years old from 19 institutions who underwent ESD for EGC between January 2006 and December 2020. We adapted the Geriatric Nutritional Risk Index (GNRI) and analyzed the associations between GNRI and major adverse events post-ESD bleeding or perforation using logistic regression analysis. Subsequently, we performed the Cox proportional hazard model to elucidate whether age-related factors were associated with three-year overall survival. Results GNRI was significantly related with post-ESD bleeding [odds ratio (OR), 0.98; 95% confidence interval (CI), 0.96–1.00, p = 0.003]. Age (hazard ratio (HR); 95% CI 1.12 [1.02–1.22], p = 0.002), male (2.29 [1.24–3.34], p = 0.005), ECOG-Performance status (1.31 [1.16–1.75], p = 0.006), Charlson Comorbidity Index (1.17 [1.03–1.33], p = 0.002), and poor GNRI (0.92 [0.90–0.94], p < 0.001) were significantly correlated with three-year overall survival. Conclusions Nutritional status was associated with post-ESD bleeding. Nutritional status and comorbidities were related with prognosis after gastric ESD. Therefore, indications of gastric ESD in patients ≥ 85 years old need to be considered with age-related comorbidities.
- 7 November 2025
- Published by Springer Nature in Surgical Endoscopy
- p. 1-12
Factors associated with adverse events and three-year survival following endoscopic submucosal dissection for early gastric cancer in patients aged 85 years or older
Background Endoscopic submucosal dissection (ESD) is a safe and minimally invasive procedure for early gastric cancer (EGC). However, little is known about the adverse events and prognosis of gastric ESD in much older adult patients with age-related comorbidities. Therefore, we aimed to elucidate factors associated with the adverse events and prognosis of ESD for EGC in patients ≥ 85 years. Methods We enrolled 853 patients with 920 lesions ≥ 85 years old from 19 institutions who underwent ESD for EGC between January 2006 and December 2020. We adapted the Geriatric Nutritional Risk Index (GNRI) and analyzed the associations between GNRI and major adverse events post-ESD bleeding or perforation using logistic regression analysis. Subsequently, we performed the Cox proportional hazard model to elucidate whether age-related factors were associated with three-year overall survival. Results GNRI was significantly related with post-ESD bleeding [odds ratio (OR), 0.98; 95% confidence interval (CI), 0.96–1.00, p = 0.003]. Age (hazard ratio (HR); 95% CI 1.12 [1.02–1.22], p = 0.002), male (2.29 [1.24–3.34], p = 0.005), ECOG-Performance status (1.31 [1.16–1.75], p = 0.006), Charlson Comorbidity Index (1.17 [1.03–1.33], p = 0.002), and poor GNRI (0.92 [0.90–0.94], p < 0.001) were significantly correlated with three-year overall survival. Conclusions Nutritional status was associated with post-ESD bleeding. Nutritional status and comorbidities were related with prognosis after gastric ESD. Therefore, indications of gastric ESD in patients ≥ 85 years old need to be considered with age-related comorbidities.
- Open Access
- 2 June 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (11)
Polybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer
Mutations in Polybromo 1 ( PBRM1 ), a subunit of the switch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complex, are frequently observed in several cancers, including pancreatic ductal adenocarcinoma (PDAC). In this study, we demonstrated that pancreas-specific loss of Pbrm1 in mice harboring Kras mutations and Trp53 deletions accelerated the development of poorly differentiated PDAC, epithelial-mesenchymal transition (EMT), and metastasis, resulting in worsened prognosis. Pbrm1 loss in preexisting PDAC shifted the tumor grade from a well- to a poorly differentiated state and elevated vimentin expression. Pbrm1 -null PDAC exhibited downregulation of apical junction genes and upregulation of EMT pathway genes, including the vimentin and squamous molecular subtype signature genes. Mechanistically, PBRM1 bound to the vimentin gene promoter and directly downregulated its expression. Furthermore, suppression of vimentin in Pbrm1 -null PDAC cells reversed the dedifferentiation phenotype and reduced EMT and metastasis. Consistently, reduced PBRM1 expression correlated with high vimentin expression, poorly differentiated histology, a high recurrence rate, and reduced overall survival in human PDACs. Additionally, PDAC with PBRM1 deletion was associated with the aggressive squamous molecular subtype. Our data established PBRM1 as a tumor suppressor that controls tumor grade and metastasis of PDAC by regulating vimentin expression.
- 2 June 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (11)
Open AccessPolybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer
Mutations in Polybromo 1 ( PBRM1 ), a subunit of the switch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complex, are frequently observed in several cancers, including pancreatic ductal adenocarcinoma (PDAC). In this study, we demonstrated that pancreas-specific loss of Pbrm1 in mice harboring Kras mutations and Trp53 deletions accelerated the development of poorly differentiated PDAC, epithelial-mesenchymal transition (EMT), and metastasis, resulting in worsened prognosis. Pbrm1 loss in preexisting PDAC shifted the tumor grade from a well- to a poorly differentiated state and elevated vimentin expression. Pbrm1 -null PDAC exhibited downregulation of apical junction genes and upregulation of EMT pathway genes, including the vimentin and squamous molecular subtype signature genes. Mechanistically, PBRM1 bound to the vimentin gene promoter and directly downregulated its expression. Furthermore, suppression of vimentin in Pbrm1 -null PDAC cells reversed the dedifferentiation phenotype and reduced EMT and metastasis. Consistently, reduced PBRM1 expression correlated with high vimentin expression, poorly differentiated histology, a high recurrence rate, and reduced overall survival in human PDACs. Additionally, PDAC with PBRM1 deletion was associated with the aggressive squamous molecular subtype. Our data established PBRM1 as a tumor suppressor that controls tumor grade and metastasis of PDAC by regulating vimentin expression.
- Open Access
- 6 February 2025
- Published by Elsevier in European Journal of Cell Biology
- Vol. 104 (2) , 151478
Mouse colorectal cancer organoids: Lessons from syngeneic and orthotopic transplantation systems
- 6 February 2025
- Published by Elsevier in European Journal of Cell Biology
- Vol. 104 (2) , 151478
Open AccessMouse colorectal cancer organoids: Lessons from syngeneic and orthotopic transplantation systems
- Open Access
- 3 December 2024
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 19 (3) , 101435
Retinoblastoma-binding Protein 9 Suppresses Intestinal Inflammation and Inflammation-induced Tumorigenesis in Mice
- 3 December 2024
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 19 (3) , 101435
Open AccessRetinoblastoma-binding Protein 9 Suppresses Intestinal Inflammation and Inflammation-induced Tumorigenesis in Mice
- Open Access
- 16 November 2024
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 60 (1) , 127-128
Cancer pathways in serrated polyposis syndrome: is conventional more crucial than serrated?
- 16 November 2024
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 60 (1) , 127-128
Open AccessCancer pathways in serrated polyposis syndrome: is conventional more crucial than serrated?